Cheryl E. G. Leyns - Concepedia

Author

Cheryl E. G. Leyns

Washington University in St. Louis ORCID

Also Known As

Cheryl E. G. Leyns, Cheryl E.G. Leyns, Cheryl Leyns, Leyns, Cheryl Elizabeth Grace

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Washington University in St. Louis Hope Center for Neurological Disorders Merck & Co., Inc., Rahway, NJ, USA (United States)Institute on Aging University of Pennsylvania

About

Cheryl E. G. Leyns is an author at Washington University in St. Louis specializing in medicine, cell biology, and neuroinflammation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	1.1K
2	Cell Biology	3	3	1.1K
3	Immunology	2	2	756
4	Health Sciences	1	1	502
5	Social Sciences	1	1	254

Cheryl E. G. Leyns

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy Cheryl E. G. Leyns, Jason D. Ulrich, Mary Beth Finn, Proceedings of the National Academy of Sciences Tau PathologyImmunologyCell DeathNeurochemical BiomarkersSynaptic Signaling	2017	502
TREM2 function impedes tau seeding in neuritic plaques Cheryl E. G. Leyns, Maud Gratuze, Sneha Narasimhan, Nature Neuroscience Signal TransductionTrem2 Function ImpedesDegenerative PathologyMedicineCell Biology	2019	335
Impact of TREM2R47H variant on tau pathology–induced gliosis and neurodegeneration Maud Gratuze, Cheryl E. G. Leyns, Andrew D. Sauerbeck, Journal of Clinical Investigation ImmunologyPathologySynaptic SignalingSocial SciencesNeuroinflammation	2020	254
Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation Fan Liao, Aimin Li, Monica Xiong, Journal of Clinical Investigation	2018	177
Targeting tauopathy with engineered tau-degrading intrabodies Gilbert Gallardo, Connie Wong, Sara M. Ricardez Hernandez, Molecular Neurodegeneration	2019	62
AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy Christina Ising, Gilbert Gallardo, Cheryl E. G. Leyns, The Journal of Experimental Medicine	2017	56
Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson’s disease Cheryl E. G. Leyns, Alice Prigent, Brenna Beezhold, npj Parkinson s Disease	2023	35
LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression Noah Lubben, Julia K. Brynildsen, Connor M. Webb, Translational Neurodegeneration	2024	17
Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson’s Disease Solomon D. Kattar, Anmol Gulati, Kaila A. Margrey, Journal of Medicinal Chemistry	2023	16
Cord Blood Erythropoietin and Hepcidin Reflect Lower Newborn Iron Stores due to Maternal Obesity during Pregnancy Colin Korlesky, Pamela J. Kling, Daphne Q.‐D. Pham, American Journal of Perinatology	2018	11

Page 1